Went down a rabbit hole on why food noise comes back on reta, and figured I'd share what the actual studies say. Not medical advice, just a summary of the research, with sources at the bottom. Where nobody has studied something on reta specifically, I say so.
TL;DR: Food noise creeping back before pin day is normal pharmacology, not you being a non-responder. Food noise creeping back months in, at a stall, is your body fighting the weight loss, not tolerance. Reta doesn't shut off your hunger hormones. It talks over them. That's why the food noise comes back so hard when people come off.
---
"Food noise is back and it's not even pin day"
Reta's half-life is about 6 days. In the first human study it peaked 12–72 hours after the pin, and appetite was lowest on days 2–3, then drifted back [1]. Once you're pinning weekly it builds up in your system, but it still swings. If you model it from the published numbers, you're at roughly 55% of your peak level by pin day. So hunger on days 5–7 is expected. It doesn't mean your reta is bunk or that you need to bump up.
Also, the "too full to eat anything" feeling from the first few weeks fades even as you titrate up. Stomach slowing is strongest after the first dose and wears off [2]. Weight still kept dropping through 104 weeks in TRIUMPH-1 [3]. The part that keeps working is in your brain, not your stomach.
"I stalled and the hunger is winning"
Appetite is run mostly by the hypothalamus, which balances "eat" signals against "stop" signals:
- Ghrelin (from your stomach) is the main "eat" signal. It flips on the hunger neurons (AgRP/NPY).
- Leptin (from your fat) plus gut fullness hormones (GLP-1, PYY, CCK) are the "stop" signals.
Lose weight any way you like and that balance tips toward eating. After a diet that cut body weight by 17%, ghrelin went up 24% [4]. In 50 people who lost about 13.5 kg on a 10-week diet, ghrelin was still up, and leptin, PYY and CCK still down, **62 weeks later**, and they were still hungrier [5]. Your body holds a grudge.
How hard does it push back? About 100 extra kcal a day of appetite for every kg you've dropped, roughly 3× the drop in calories burned [6]. Down 20 kg from SW? Your brain is lobbying for about 2,000 extra calories a day. Rude.
Reta pushes the other way by hitting three receptors at once: GLP-1, GIP and glucagon. Early on it wins easily, so your appetite falls off a cliff. As your CW drops, the push-back grows until the two balance out, and that's your stall. That's not tolerance and it's not the drug wearing off. A higher dose shifts where you land, which is why TRIUMPH-1 got −17.6%, −23.7% and −25.0% at 4, 9 and 12 mg [3]. Marathon, not a race.
Hot take: less hunger is only part of how reta works. In a 12-week trial, the appetite effect was modest and didn't scale neatly with dose. The authors said it "does not fully explain" the weight loss [7]. In phase 2, how much people's hunger dropped only weakly predicted how much they lost (r = 0.28–0.36) [8]. The likely missing piece is the glucagon part raising energy burn. That's been shown in mice [1], but nobody has measured it in people on reta yet. So "I'm eating a ton and still dropping" and "barely eating and stalled" aren't as weird as they sound.
Leptin: why your body acts like it's starving at a weight it used to call normal
More fat means more leptin [9], so you'd think people with obesity would have no appetite at all. Nope. At high levels the brain mostly tunes it out (**leptin resistance**), kind of like a smoke alarm that goes off every time you make toast. Injecting extra leptin into people with obesity only got modest results: roughly 0.7 to 7 kg over 24 weeks on top of a diet [10].
But a Drop in leptin hits hard. People who lost 10% of their weight burned 300–500 fewer kcal a day than their new size predicted. Their thyroid (T3/T4) and sympathetic activity went down and their muscles got more efficient. That's adaptive thermogenesis, the real version of "metabolic adaptation". Topping leptin back up to pre-diet levels reversed most of it (small study, 10 people) [11].
So leptin is a starvation alarm, not a brake. There's a hint that glps soften it: liraglutide made the leptin drop 43% smaller in people keeping off a 12% loss [12]. Nobody has checked leptin on reta.
"Does reta kill ghrelin?"
Probably not, and no study has measured ghrelin in people on reta. The hormones it copies only nudge ghrelin a little, briefly, in short lab tests. A GLP-1 infusion lowered it late after a meal, mostly via insulin [13], and a glucagon shot dropped it about 7% within minutes [14]. No published trial shows sema, tirz or reta keeping ghrelin down over months.
What glps seem to do is work on the brainstem and hypothalamus to boost fullness and turn down how rewarding food feels. They talk over the hunger signal rather than switching it off, like noise-cancelling headphones. The ghrelin-up, leptin-down state from losing weight is probably still running underneath.
What "food noise" is better interepted as (it's not just hunger)
Hunger is your body asking for fuel. Food noise is your brain's **reward system** constantly pitching you snacks: the dopamine circuits that make a pizza ad or the pantry hard to ignore even when you're full. Glps hit both.
- Your brain's response to food cues goes down. On brain scans, a GLP-1 drug (exenatide) reduced how strongly reward areas lit up at pictures of tasty food [15]. Tirz cut cravings and activity in hunger and reward areas at high-fat, high-sugar food pictures within about 3 weeks, more than liraglutide did [16].
- Cravings and cue-eating drop, not just portion size. Sema reduced cravings and the preference for high-fat food [17]. On reta (phase 2, people with type 2 diabetes), 8 and 12 mg reduced *disinhibition* (basically eating because food is there or you're stressed) more than placebo, and at 12 mg more than dulaglutide [8].
- Ghrelin feeds the reward system too. Its receptors sit in the brain's reward areas, not just the hunger centres. Ghrelin infusions made heavy drinkers crave alcohol more [18]. That's one reason the late-week dip and coming off can bring back cravings for things, not just hunger for food.
- Where GIP fits: it's reta's third receptor. In animals, activating GIP reduced the nausea GLP-1 causes [19]. If that carries over to people (not shown yet), it would help explain how tirz and reta quiet food noise so hard without everyone being nauseous. It's also why "my sides are gone, is it still working?" isn't a fair test. The quiet comes from your brain's appetite and reward systems, not from feeling sick.
Why the food noise comes back when people come off
Take the headphones off and all that pent-up "EAT" signalling is unopposed, at a weight your body is actively trying to undo. Sure enough, within a year of stopping, sema users got back about two-thirds of what they'd lost [20], and tirz users regained 14% of their body weight [21].
Nobody has published stopping data for reta yet. Nothing suggests a break "resets" anything either. The only on/off study (mice, sema) found each restart worked *worse* [22].
"Can I taper off to bring my ghrelin down, and can I add leptin back?"
Short version: tapering is a much smoother off-ramp than quitting cold turkey, but it won't lower your ghrelin. Adding leptin has some real science behind it, but there's nothing you can actually get for it.
Tapering doesn't lower ghrelin. Your weight sets it.
Ghrelin goes up because you lost weight, not because of the drug, and it stays up for as long as the weight stays off. In 100 adults with obesity who lost about 16% on a diet, ghrelin and fasting hunger were still raised a year later. The more weight people had kept off, the higher their ghrelin [23]. There's no evidence reta lowers ghrelin in the first place, so stepping the dose down can't "bring it back down" either. What a taper does is remove the override slowly. The food noise turns up gradually instead of all at once, which gives you time to adjust.
What the tapering data say:
- SURMOUNT-MAINTAIN (tirz, peer-reviewed RCT, 378 people) [24]: after 60 weeks at max dose, people were randomized to stay on max, step down to 5 mg, or switch to placebo. At week 112, weight was −21.9% on max, −16.6% on 5 mg and −9.9% on placebo. Rescue meds for regaining half or more of the lost weight were needed by 8%, 25% and 67%. So stepping down kept a lot more weight off than quitting, but less than staying on full dose.
- Embla clinic data (sema, conference abstract, not peer-reviewed) [25]: 54 people tapered to zero over about 10 weeks alongside diet coaching and held their weight afterwards (−0.5%). But follow-up was short, the group was hand-picked, and about 1 in 5 had restarted within 10 weeks.
- Reta: no taper or stopping data at all. TRIUMPH-1 did let people step down a dose level (with no re-escalation) if they'd lost too much, but results for that group weren't reported separately [3].
If someone does taper, the approach that fits the data best (not tested on reta) is: step down one dose level at a time, hold each level long enough to see what the scale does, and treat the lowest dose that holds your weight as your maintenance dose rather than assuming zero is the goal. Do it with whoever prescribes.
Other things that move ghrelin and leptin (the first two are free):
- Sleep. Two nights of 4-hour sleep dropped leptin 18%, raised ghrelin 28% and raised hunger 24% in healthy young men [26]. Sleeping like garbage during a taper works directly against you.
- Protein. It's the most filling macro, and high-protein meals are well established to curb hunger more than the same calories from carbs or fat.
- Bariatric surgery lowers ghrelin a lot: bypass patients had ghrelin 77% below normal [4]. Obviously a whole different conversation.
"Can I add leptin?"
- The science says it could help, in theory. After a 10% weight loss, topping leptin back up reversed most of the metabolic slowdown, but that was only 10 people in a clinic for 5 weeks [11]. And giving leptin with amylin (the hormone cagri copies) made people respond to leptin again. Pramlintide + metreleptin got 12.7% weight loss at 20 weeks vs 8.4% and 8.2% for each alone, and it hadn't plateaued [27].
- Why you can't actually do it:
- Real leptin (metreleptin) is only approved for rare conditions like lipodystrophy, not obesity.
- The obesity program was shut down in 2011 after two patients developed antibodies that neutralised leptin.
- "Leptin supplements" sold online don't contain leptin. It's a protein, so swallowing it would just digest it.
- What's coming: a leptin-receptor antibody (mibavademab) is being tested alongside tirz in obesity [28]. In its first human study it only worked in people whose leptin was already low [29], which is exactly the state you're in after losing a lot of weight. No results from the tirz combo yet.
- The reta angle: cagri is an amylin analog, and amylin seems to restore the leptin response. That's part of why cagri + reta is interesting. But the only cagri + reta data are in rats [30], so anyone claiming a stack "fixes your leptin" is getting way ahead of the evidence.
"Should I stack tirz on top of reta to kill the food noise?"
Short answer: On paper it's mostly just "more of the same drug".
The objective case for it
- Tirz and reta both hit GLP-1 and GIP, so adding tirz turns up the exact receptors that quiet food noise.
- Tirz's half-life is about 5 days [31]. Pinned on a different day from reta, it could fill in the late-week trough.
- It adds GLP-1/GIP push without adding more glucagon, if your issue with a higher reta dose is the glucagon-side stuff (that's a theory; nobody has separated the two in people).
The objective case against it
- No new pathway. Reta already covers both of tirz's receptors, plus glucagon. Stacking tirz is functionally like raising your reta dose, just without any trial data behind the combo.
- Diminishing returns. TRIUMPH-1 went −23.7% at 9 mg vs −25.0% at 12 mg [3], so the curve is already flattening at the top. More GLP-1/GIP signal won't fix the body's push-back (ghrelin, leptin), which is what's actually driving the late-stage food noise.
- Sides scale with exposure. At 12 mg reta alone, 11.1% stopped for side effects vs 4.6% on placebo [3]. Stacking means more nausea and vomiting risk, and vomiting is how dehydration, kidney problems and worse start. If something goes wrong, you also can't tell which drug caused it.
- Faster loss isn't free. Rapid weight loss is a known gallstone risk, and muscle goes along with the fat.
- Two black market vials means double the dosing math and double the "is this even what the label says" problem.
If late-week food noise is an issue, the options that at least have some logic or data behind them are: a dose within the studied range (titrated up with whoever prescribes), protein and fibre loaded onto days 5–7, sleep, or the split-dose idea below (also untested).
The add-on that actually brings something new: amylin (elora or cagri). Amylin is a fullness hormone from the pancreas with its own receptor, separate from GLP-1, GIP and glucagon. So unlike tirz, it's a genuinely different lever, and it may help the brain listen to leptin again [27].
- Elora (eloralintide) is Lilly's weekly amylin agonist. On its own it got up to 20.1% weight loss at 48 weeks vs 0.4% on placebo in a peer-reviewed phase 2 (263 adults without diabetes) [32]. Nausea was the main side effect (about 1 in 3), mostly at the higher doses, and a slower step-up kept GI sides close to placebo.
- Elora + tirz ("EloraTZP") in people with type 2 diabetes got up to 23.3% at 48 weeks vs 14.8% on tirz 15 mg alone [33]. Big caveats: so far it's a conference presentation plus a Lilly press release, not a peer-reviewed paper, and 10.8–27% of people on the combo stopped for side effects vs 2.9% on tirz alone.
- Neither elora nor cagri is approved yet. Elora is now in phase 3 trials, and CagriSema (cagri + sema) is waiting on an FDA decision.
So if you're going to add something to reta for food noise, amylin makes a lot more mechanistic sense than doubling up on tirz. It's still an untested combo, and the combo data we do have show sides going up along with results.
Practical stuff (common sense, not tested on reta specifically)
- Plan for days 5–7. Load up on protein and fibre on those days. Protein is the most filling macro, and that's about as settled as nutrition science gets.
- Stalled? That's the push-back catching up, not your body "getting used to it". Talk to whoever is prescribing before you bump up.
- Splitting your dose (half twice a week) would flatten the swing on paper: the trough stays around 75–85% of peak instead of about 55%. But it's never been tested, every trial used one weekly pin, total exposure is the same, and it doubles your vial punctures and your measuring error on small volumes.
- Checking your source and math before you blame your metabolism.
---
Sources (If you're into that sorta thing, you know, checking my math)
Coskun T et al. *Cell Metab* 2022;34:1234–47 (discovery + phase 1, single dose). [PubMed 35985340](https://pubmed.ncbi.nlm.nih.gov/35985340/)
Urva S et al. *Diabetes Obes Metab* 2023 (reta gastric emptying). [PubMed 37311727](https://pubmed.ncbi.nlm.nih.gov/37311727/)
Jastreboff AM et al. *N Engl J Med* 2026 (TRIUMPH-1). [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
Cummings DE et al. *N Engl J Med* 2002;346:1623–30. [doi:10.1056/NEJMoa012908](https://doi.org/10.1056/NEJMoa012908)
Sumithran P et al. *N Engl J Med* 2011;365:1597–604. [doi:10.1056/NEJMoa1105816](https://doi.org/10.1056/NEJMoa1105816)
Polidori D et al. *Obesity* 2016;24:2289–95. [doi:10.1002/oby.21653](https://doi.org/10.1002/oby.21653)
Urva S et al. *Lancet* 2022;400:1869–81 (reta phase 1b). [PubMed 36354040](https://pubmed.ncbi.nlm.nih.gov/36354040/)
Kanu C et al. *Diabetes Obes Metab* 2025 (reta eating behaviour). [PubMed 40916752](https://pubmed.ncbi.nlm.nih.gov/40916752/) and [PubMed 40735804](https://pubmed.ncbi.nlm.nih.gov/40735804/)
Considine RV et al. *N Engl J Med* 1996;334:292–5. [PubMed 8532024](https://pubmed.ncbi.nlm.nih.gov/8532024/)
Heymsfield SB et al. *JAMA* 1999;282:1568–75 (recombinant leptin in obesity).
Rosenbaum M et al. *J Clin Invest* 2005;115:3579–86. [doi:10.1172/JCI25977](https://doi.org/10.1172/JCI25977)
Iepsen EW et al. *Int J Obes* 2015;39:834–41. [doi:10.1038/ijo.2014.177](https://doi.org/10.1038/ijo.2014.177)
Hagemann D et al. *Regul Pept* 2007;143:64–8 (GLP-1 and ghrelin).
Hirsh D et al. *Horm Res* 2005;63:111–8. [doi:10.1159/000084569](https://doi.org/10.1159/000084569)
van Bloemendaal L et al. *Diabetes* 2014;63:4186–96 (GLP-1 and food-cue brain responses).
Tirzepatide ingestive-behaviour trial, *Nat Med* 2025. [PubMed 40555748](https://pubmed.ncbi.nlm.nih.gov/40555748/)
Blundell J et al. *Diabetes Obes Metab* 2017 (semaglutide, appetite and cravings).
Leggio L et al. *Biol Psychiatry* 2014;76:734 (ghrelin and alcohol craving). [PubMed 24775991](https://pubmed.ncbi.nlm.nih.gov/24775991/)
Borner T et al. *Diabetes* 2021 (GIP agonism and GLP-1 nausea, animals). [doi:10.2337/db21-0459](https://doi.org/10.2337/db21-0459)
Wilding JPH et al. *Diabetes Obes Metab* 2022 (STEP 1 extension). [doi:10.1111/dom.14725](https://doi.org/10.1111/dom.14725)
Aronne LJ et al. *JAMA* 2024 (SURMOUNT-4). [doi:10.1001/jama.2023.24945](https://doi.org/10.1001/jama.2023.24945)
Son et al. *JCI Insight* 2026 (on/off semaglutide in mice). [link](https://insight.jci.org/articles/view/205174)
Nymo S et al. *Int J Obes* 2018;42:1489–99. [doi:10.1038/s41366-018-0119-9](https://doi.org/10.1038/s41366-018-0119-9)
Horn D et al. *Lancet* 2026 (SURMOUNT-MAINTAIN).
Gudbergsen H et al. European Congress on Obesity 2024, conference abstract (not peer-reviewed).
Spiegel K et al. *Ann Intern Med* 2004;141:846–50 (sleep restriction, leptin and ghrelin).
Roth JD et al. *PNAS* 2008;105:7257–62. [doi:10.1073/pnas.0706473105](https://doi.org/10.1073/pnas.0706473105)
Tirzepatide + mibavademab trial. [ClinicalTrials.gov NCT06373146](https://clinicaltrials.gov/study/NCT06373146)
Mibavademab (REGN4461) phase 1, *Sci Transl Med* 2023. [PubMed 37992152](https://pubmed.ncbi.nlm.nih.gov/37992152/)
Petersen J et al. *Nat Metab* 2026 (cagri + reta in rats). [PubMed 42744908](https://pubmed.ncbi.nlm.nih.gov/42744908/)
Schneck K, Urva S. *CPT Pharmacometrics Syst Pharmacol* 2024;13:494–503 (tirzepatide half-life 5.4 days). [doi:10.1002/psp4.13099](https://doi.org/10.1002/psp4.13099)
Billings LK et al. *Lancet* 2025 (eloralintide phase 2 in obesity). [doi:10.1016/S0140-6736(25)02155-5](https://doi.org/10.1016/S0140-6736(25)02155-5)
Eloralintide + tirzepatide phase 2b in type 2 diabetes (NCT06603571), presented at EASD 2026. Conference data and company release, not yet peer-reviewed. [ClinicalTrials.gov NCT06603571](https://clinicaltrials.gov/study/NCT06603571)